Mechelen, Belgium; 28 February 2008 - Galapagos NV (Euronext & LSE: GLPG) announced today that it has selected pre-clinical candidates in its rheumatoid arthritis and bone metastasis programs. It is the Company’s intention to submit IND (Investigational New Drug) applications for these programs later this year, with initiation of clinical trials for bone metastasis by yearend and for rheumatoid arthritis early 2009. The Company also intends to select a pre-clinical candidate in osteoarthritis in 2008. Progress on these and other drug discovery programs will be discussed during the webcast this afternoon.
